CAR-T Cells in the Treatment of Malignant Hematological Tumors

To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

With the consent of himself or the legal guardian and the signed informed consent, he is willing and able to comply with the planned visit, research and treatment, laboratory examination and other test procedures; Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic TumorPatients with recurrent and refractory hematopoiesis and lymphoid tissue tumors determined by clinical diagnosis;Age 14-70 (including boundary value), both male and female;Subjects with a physical status of 0~2 in the American Eastern Oncology Collaboration Group (ECOG);The results of treatment related antigens were positive;The expected life span is more than 3 months from the date of signing the informed consent;